Document is current
Any future updates will be listed below
-
Authors
Lieberman, S. https://orcid.org/0000-0003-1671-6444
Chen-Shtoyerman, R.
Levi, Z.
Shkedi-Rafid, S.
Zuckerman, S.
Bernstein-Molho, R.
Levi, G. Reznick
Shachar, S. S.
Flugelman, A.
Libman, V.
Kedar, I.
Naftaly-Nathan, S.
Lagovsky, I.
Peretz, T.
Karminsky, N.
Carmi, S.
Levy-Lahad, E.
Goldberg, Y.
-
Funding
Funding for this research was provided by:
Israeli Cancer Association (Israeli Breast Cancer Consortium)
Israeli Cancer Association (Identification of minorities with cancer genes)
- License Information
-
More Information
Article History
Received: 25 January 2022
Accepted: 22 February 2022
First Online: 12 March 2022
Declarations
:
: Author S.L. has received a speaker honorarium from AstraZeneca Company. Author S.C. is a paid consultant at MyHeritage.
: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Boards of the participants’ genetic institutes: Shaare Zedek (SZMC- 10–11) Rabin (RMC- 0161–17), Kaplan (KMC-156–13), Shiba (SZMC-8470–21), Rambam (RMB-0559–16), Hadassah (04401–9), and Shamir (ASF-0006–20).
: Patient consent was waived by IRB approval since the study is a retrospective study of anonymized data.
: All the authors have read and approved the final version of the manuscript.
